A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer:

Martin Metzenmacher,Hans Georg Kopp,Frank Griesinger,Niels Reinmuth,Martin Sebastian,Monika Serke,Cornelius F. Waller,Michael Thomas,Jochen Eggert,Gerald Schmid-Bindert,Mathias Hoiczyk,Daniel C. Christoph,Martin Kimmich,Burkhard Deuß,Stephanie Seifert,Swantje Held,Martin Schuler,Thomas Herold,Frank Breitenbuecher,Wilfried Eberhardt

A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer:

2021

Background:Pemetrexed and cisplatin is a first-line standard in non-squamous non-small-cell lung cancer without targetable mutations. It became the backbone of checkpoint-inhibitor–chemotherapy com...

Keywords:

Cisplatin
Oncology
Lung cancer
Tolerability
Medicine
Internal medicine
Pemetrexed
Dosing
Phases of clinical research
Chemotherapy
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations